
FDA OKs first biosimilar of Roche's blockbuster AMD drug Luc...
Samsung Bioepis and Biogen have claimed the first FDA approval for a biosimilar version of Roche and Novartis' Lucentis (ranibizumab) for leading causes of blindness, raising the prospect o